share_log

Oppenheimer Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $50

Oppenheimer Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $50

奥本海默以跑赢大盘的评级启动对Immunovant的报道,宣布目标股价为50美元
Moomoo 24/7 ·  03/28 06:49

Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Price Target of $50.

奥本海默分析师利兰·格舍尔开始对Immunovant(纳斯达克股票代码:IMVT)进行报道,评级为跑赢大盘,并宣布目标股价为50美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发